{
    "nct_id": "NCT03249090",
    "official_title": "\"PRO-TECT\" Patient Reported Outcomes to Enhance Cancer Treatment",
    "inclusion_criteria": "1. Adults (21+) with metastatic cancer of any type (EXCEPT leukemia or indolent [slow growing] lymphoma)\n2. Receiving outpatient systemic cancer treatment for non-curative/palliative intent, including chemotherapy, targeted therapy, or immunotherapy.\n3. Enrolled at any point in their treatment trajectory, meaning during any line of treatment, and at any point during a course or cycle of treatment.\n4. Can understand English, Spanish, and/or Mandarin Chinese.\nHealthy volunteers allowed\nMust have minimum age of 21 Years",
    "exclusion_criteria": "1. Cognitive deficits that would preclude understanding of consent form and/or questionnaires.\n2. Current participation in a therapeutic clinical trial (because these often involve PRO questionnaires and intensive monitoring).\n3. Patients being treated with curative intent (e.g., adjuvant chemotherapy for breast, lung, or ovarian cancer; primary curative therapy for testis cancer or lymphoma).\n4. Receiving hormonal therapy only (e.g., tamoxifen or aromatase inhibitors in breast cancer; androgen deprivation therapy in prostate cancer; or octreotide in neuroendocrine cancers)\n5. Indolent lymphomas (due to their prolonged time courses that may be minimally symptomatic).\n6. Leukemias (time courses inconsistent with other tumor types in chronic and acute leukemias).\n7. Does not understand English, Spanish, or Mandarin Chinese.",
    "miscellaneous_criteria": ""
}